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Abstract 
Aims: Cardiac pressure and humoral factors induce cardiac hypertrophy and fibrosis, 
which are characterized by increased stiffness, reduced contractility and altered 
perfusion. Angiotensin II (AngII) is well known to promote this pathology. 
Angiotensin-converting enzyme (ACE) 2, which cleaves AngII and forms Ang-(1–7), 
exerts protective anti-hypertrophy and anti- fibrosis effects. A disintegrin and 
metalloproteinase 17 (ADAM17), a membrane-bound enzyme reported to cleave 
ACE2, may participate in the pathological process of AngII perfusion- induced heart 
damage. However, researchers have not clearly determined whether dickkopf-3 
(DKK3) regulates the ADAM17/ACE2 pathway and, if so, whether DKK3-mediated 
regulation is related to the glycogen synthase kinase-3β (GSK-3β)/β-catenin pathway. 
In this study, we explored whether DKK3 overexpression ameliorates the 
development of AngII- induced cardiac fibrosis and hypertrophy through the 
ADAM17/ACE2 and GSK-3β/β-catenin pathways. 
Methods: Mice were injected with a DKK3-overexpressing adenovirus or vehicle and 
then infused with AngII or saline using subcutaneously implanted mini-pumps for 
four weeks. Hearts were stained with hematoxylin-eosin, Masson’s trichrome and 
immunohistochemical markers for histology. Primary fibroblasts were treated with the 
adenovirus and AngII and then examined using western blotting, EdU 
(5-Ethynyl-2’-deoxyuridine) assays and immunofluorescence. Additionally, siRNA 
silencing was performed to study the role of DKK3 and the involved pathways.  
Results: AngII-induced cardiac hypertrophy and interstitial and perivascular fibrosis 
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were less severe in DKK3-overexpressing mice than in control mice. Moreover, the 
expression levels of fibrotic genes, such as collagen I and III, and the hypertrophic 
genes atrial natriuretic peptide (ANP) and beta-myosin heavy chain (β-MHC) were 
decreased. DKK3 overexpression also exerted a protective effect by inhibiting 
ADAM17 phosphorylation, thus increasing ACE2 expression and subsequently 
promoting AngII degradation. Furthermore, this process was mediated by the 
inhibition of GSK-3β and β-catenin and decreased translocation of β-catenin to the 
nucleus. On the other hand, the DKK3 knockdown by siRNA achieved opposite 
results.  
Conclusion: DKK3 overexpression substantially alleviated AngII infusion- induced 
cardiac hypertrophy and fibrosis by regulating ADAM17/ACE2 pathway activity and 
inhibiting the GSK-3β/β-catenin pathway. 
Keywords: DKK3, ADAM17/ACE2, GSK-3β/β-catenin, cardiac hypertrophy, 
fibrosis, angiotensin 
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Introduction 
Cardiac hypertrophy is a maladaptive reaction in response to pressure or volume 
stress. The main pathological changes in cardiac hypertrophy present as changes with 
many aspects, including myocardial interstitial cell hypertrophy, myocardial 
interstitial cell proliferation, and extracellular matrix increase of myocardial cells, 
thus leading to myocardial remodeling [1]. Fibrosis constitutes a major hypertrophic 
pathological development in addition to myocardial cell hypertrophy. In the 
pressure-overloaded heart, myocardial cells undergo hypertrophy to increase their 
strength, and the heart size changes slightly at first; however, under persistent 
high-pressure conditions, the heart enters a decompensatory period and undergoes 
eccentric hypertrophy. Zhang et al studied pressure overload-induced cardiac 
hypertrophy in a mouse model using the aortic banding method. They focused on a 
small molecule called dickkopf-3 (DKK3), which also aroused our interest. DKK3, a 
secreted protein in the dickkopf family, is a robust inhibitor of the Wnt signaling 
pathway. The dickkopf gene family comprises four evolutionarily conserved members 
(DKK 1-4) and dickkopf-like acrosomal protein 1 (DKKL1) or soggy. Multiple studies 
have reported DKK3 down-regulation in a variety of cancer cell lines and tissues [11, 
12]. In the study by Zhang et al, DKK3 was reported to act as a cardioprotective 
regulator of pressure-induced cardiac hypertrophy via the regulation of 
ASK1-JNK/p38 signaling. Moreover, neurohumoral factors such as the 
renin-angiotensin system (RAS), aldosterone, catecholamine and endothelin, are 
common causes of cardiac hypertrophy. Among these factors, the RAS is the main and 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
most influential pathogenic factor. Several studies have indicated that activation of the 
RAS contributes to cardiac remodeling [5-7]. Angiotensin II (AngII) has a central role 
in mediating most of the effects of the RAS and is a key trigger of heart hypertrophy 
and fibrosis [8]. Angiotensin-converting enzyme (ACE) 2 is an enzyme that 
hydrolyzes AngII into Ang-(1–7) [9]. Ang-(1–7) also has a broad range of effects on 
cardiovascular tissues, such as improving vascular endothelial function, decreasing 
matrix metalloproteinase 9 (MMP9) expression and reducing neutrophil and 
macrophage infiltration [10, 11]. Adisintegrin and metalloproteinase (ADAM) 17, 
also known as TNFα-converting enzyme (TACE), is a member of the superfamily of 
Zn-dependent metalloproteases; it is a type I transmembrane protein that plays a key 
role in regulating the proteolytic release of some cytokines, chemokines, growth 
factors and their receptors from cellular membranes [12]. ADAM17 was recently 
shown to cleave ACE2, leading to ACE2 down-regulation [13]. Aside from aortic 
banding, AngII infusion is another classical method of constructing cardiac 
hypertrophy mouse models; this method was particularly suitable for the present study 
due to the direct use of AngII. However, the mechanism by which DKK3 contributes 
to AngII-induced cardiac hypertrophy remains to be elucidated. Currently, no studies 
have examined the relationships between DKK3, ADAM17, and ACE2. Therefore, we 
proposed the hypothesis that DKK3 inhibits AngII-induced cardiac hypertrophy and 
fibrosis by decreasing ADAM17 activity and increasing ACE2 expression. Because 
DKK3 regulates the glycogen synthase kinase-3β (GSK-3β)/β-catenin pathway in 
many cell types and diseases [14-16], we determined whether DKK3 controls 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ADAM17/ACE2 via this pathway. 
The present study was designed (i) to determine whether DKK3 expression 
changes in an AngII-perfused animal model, (ii) to determine whether DKK3 
overexpression attenuates cardiac hypertrophy and fibrosis, (iii) and if so, to 
determine whether this protective response is related to the regulation of the 
ADAM17/ACE2 pathway, (iv) and whether the ADAM17/ACE2 pathway is 
modulated by the GSK-3β/β-catenin pathway. 
Methods 
2.1. Primary cultures of cardiac fibroblasts 
Primary cardiac fibroblasts (CFs) were prepared from the hearts of 1- to 3-day-old 
neonatal C57BL/6 mice, as previously described [12]. Briefly, after sacrifice by 
decapitation, the sternum of the neonatal mice was longitudinally incised to expose 
the heart. Then, the heart was isolated and cut into pieces in DMEM. The pieces were  
digested with collagenase type II for 3 h at 37°C. Then, the liquid supernatant was 
centrifuged, and cells were cultured in DMEM containing 10% fetal bovine serum 
(FBS) (Gibco, California, USA) and penicillin-streptomycin (100 U/ml penicillin, 100 
g/ml streptomycin) (Gibco, California, USA) at 37°C with 5% CO2. Two hours later, 
the culture medium was replaced to remove all cells except the CFs. The cells were 
subcultured in subsequent experiments. 
2.2. Cell transduction and drug administration  
The DKK3-overexpressing adenovirus was purchased from Abm (Cat: 190468A, 
Canada) and amplified by the Chinese National Human Genome Center, Beijing. CFs 
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were pretreated with DKK3 overexpression adenovirus or adenovirus vehicle 
(MOI=100) for 24 h before AngII (1 μg/ml) stimulation and were cultured for an 
additional 48 h to evaluate the effect of DKK3 overexpression [17]. The CFs were 
divided into six groups as follows: 
Group 1 (OV+AngII): DKK3-overexpressing adenovirus+ Angiotensin II 
Group 2 (AD+AngII): adenovirus vehicle+ Angiotensin II 
Group 3 (AngII): Angiotensin only 
Group 4(OV): DKK3-overexpressing adenovirus 
Group 5(AD): adenovirus vehicle 
Group 6 (NC): no additions 
The DKK3 small interfering experiment (siRNA) transfection experiment and 
grouping are described in detail in the supplement. 
2.3 Animal model  
Based on the results of the preliminary in vitro  experiment, the AngII group 
presented similar results as the AD+AngII group, and the results observed in the NC 
group were similar to the AD group. We removed the AngII and NC groups to 
conduct our in vivo experiment with fewer animals. Sixty male wild-type C57BL/6 
mice (10–12 weeks of age) were chronically infused with saline or AngII at a rate of 
1000 ng/kg/min using osmotic mini-pumps (Alzet, Cupertino, CA) for 28 days as 
described previously [18]. The DKK3-overexpressing adenovirus or vehicle (2×109 
pfu) [19] was administered by a caudal vein injection 3 days before the operation. On 
day 15, mice were injected again. Mice were divided into four groups randomly and 
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treated as follows: 
Group 1 (OV+AngII): DKK3-overexpressing adenovirus injection + Angiotensin II 
pumping  
Group 2 (AD+AngII): adenovirus vehicle injection + Angiotensin II pumping 
Group 3(OV): DKK3-overexpressing adenovirus injection +saline pumping 
Group 4(AD): adenovirus vehicle injection +saline pumping 
The blood pressure was measured in the tail on day 31 (three days before 
adenovirus injection plus 28 days’ angiotensin II pumping) before the mice were 
sacrificed. All animal care and experimental protocols complied with the Animal 
Management Rules of the Ministry of Health of the People’s Republic of China 
(document No 55, 2001) and were approved by the Animal Care Committee of 
Shandong University. 
2.4 Quantitative real-time RT-PCR 
Total RNA was extracted from the left ventricle of mice or CFs using TRIzol 
reagent (Invitrogen, CA). A real-time PCR thermocycler (IQ5 real-time PCR cycler; 
Bio-Rad) was utilized to perform the quantitative real-time PCR. PCR was performed 
at 95°C for 30 s, followed by 40 cycles of 95°C for 5 s and 56°C for 10 s. The 
transcript GAPDH content was quantified as an internal control. The results were 
calculated using the 2 △△CT method.  
2.5 Western blot (WB) analyses 
Total proteins and nuclear proteins were extracted from CFs or mouse cardiac 
tissues, and equal amounts of protein were electrophoretically separated and then 
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transferred to PVDF membranes. The membranes were incubated overnight at 4°C 
with a primary antibody. The antibodies used in this study were anti-DKK3, 
anti-collagen I, anti-collagen III, anti-MMP2, anti-MMP9, anti-phosphor-ADAM17 
(T735), anti-ACE2 and anti-TGF-β1 (all purchased from Abcam，Cambridge，UK), 
anti-ADAM17, anti-GSK-3β, anti-β-catenin, anti-phospho-GSK-3β (Ser9), 
anti-active-β-catenin (Ser33/37/Thr41), anti-bcl-2, anti-bax, anti-Smad3, 
anti-phospho-Smad3(Ser423/425) and anti-β-actin (all purchased from Cell Signaling 
Technology, Boston, USA). Anti-rabbit IgG and anti-mouse IgG antibodies 
(ZSGB-Bio, Peking, China.) were used as secondary antibodies. The membranes were 
developed using Immobilon Western Detection Reagents (Millipore, Billerica, MA, 
USA). 
2.6 Cell proliferation assay (EdU) 
Cell proliferation was determined with an EdU incorporation assay, as previously 
described [20]. Briefly, CFs were seeded into slides and administered different drugs 
or adenovirus the day before staining. CFs were supplemented with 1% FBS and 
20 μΜ 5-ethynyl-2’-deoxyuridine (EDU) (RiboBio, Guangzhou, China). Cells were 
fixed with 4% paraformaldehyde for 20 min and then permeabilized with 0.1% Triton 
X-100 for 30 min at room temperature. Then, 50 μl of 2 mg/ml glycine were added to 
each well to neutralize the PFA. The cells were exposed to 100 μl of Apollo-Fluor 
(RiboBio, Guangzhou, China) for 30 min in the dark at room temperature. Cells were 
stained with the 1× Hoechst 33342 solution for 30 min. Each well was washed twice 
with PBS, and images were acquired under a florescence microscope. The percentages 
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of EDU-positive cells were determined, and three independent experiments were 
performed. 
2.7 Immunofluorescence 
CFs were briefly washed with cold PBS 3 times and fixed with 4% 
paraformaldehyde for 30 min. Then, the CFs were washed thrice, blocked in 5% goat 
serum albumin for 30 min, and permeabilized using Triton X-100. Cells were 
incubated with a primary rabbit anti-active-β-catenin antibody overnight at 4°C, 
followed by an incubation with the secondary antibody (ZSGB-Bio, Peking, China). 
Nuclei were stained with DAPI for 5 min at room temperature, and 
immunofluorescence was analyzed under a florescence microscope. 
2.8 ELISA 
The level of DKK3 in mouse plasma was measured using ELISA kits (kit 50247, 
SinoBiological Inc., Wuhan, China), according to the manufacturer’s instructions. The 
levels of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) in mouse plasma 
were measured using ELISA kits (eBioscience, San Diego, USA). The level of 
Ang-(1-7) in mouse plasma was measured using an ELISA kit (J&L Biological, 
Shanghai, China). The experiment was repeated thrice, and the average number was 
adopted. 
2.9 Detection of mice echocardiography and pathological samples 
Echocardiographic imaging was performed post-operatively. The following 
parameters were tested: left ventricular ejection fraction (LVEF), ratio of early to late 
mitral inflow velocity (E/A), fractional shortening (FS), and the thickness of the left 
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ventricular diastolic posterior wall (LVPWD). Systolic blood pressure was measured 
using the tail-cuff method at 3 and 31 d as previously described [18]. Before the mice 
were sacrificed, body weights were recorded and their tibias were measured. Next, 
mice hearts were dissected and weighed to calculate the ratio to the body weight.  
Indexes were calculated including heart weight (HW)/body weight (BW) and 
HW/tibial length (TL). Mouse hearts were then photographed to observe their 
morphology. 
2.10 Histopathology and immunohistochemistry 
Mouse hearts were dissected and fixed in 4% formalin. Heart sections were 
embedded in paraffin and sectioned to 5-μm thickness for staining with hematoxylin 
and eosin (H&E). Extracellular matrix (ECM) deposition was valued by staining with 
masson's trichrome. Slides were incubated overnight with the following primary 
antibodies: rabbit anti-ACE2, anti-collagen I and III, anti-CD45, anti-CD68 and 
anti-IL-6 (all Abcam, Cambridge，UK). The sections were incubated with a goat 
antibody (ZSGB-BIO, Peking, China) as the secondary antibody. Matrix accumulation 
was quantified using Image- Pro Plus 6.0.  
2.11 Statistical analysis 
All data are expressed as the mean±standard deviations (SD). Statistical analysis 
was performed with either Student’s t-test or one-way ANOVA as appropriate. P 
values<0.05 were considered statistically significant. 
3 Results 
3.1 DKK3 overexpression alleviates AngII-induced cardiac dysfunction and 
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hypertrophy 
A mouse model of cardiac hypertrophy was constructed to determine whether 
DKK3 overexpression exerted a protective effect on myocardial hypertrophy. Mice 
were chronically infused with AngII at a rate of 1,000 ng/kg/min using osmotic 
mini-pumps for 28 days to generate cardiac hypertrophy [18]. In our experiment, mice 
in the treatment group were injected with the DKK3-overexpressing adenovirus, and 
other groups were treated as described in the Methods. First, immunoblot and ELISA 
analyses confirmed that the injection of the DKK3-overexpressing adenovirus 
elevated the DKK3 level in both the cardiac tissue and serum (Fig. 1a-1,1a-2 and 1c). 
In vitro, DKK3 adenovirus transduction also elevated DKK3 expression (Fig. 1b-1, 
1b-2). In the siRNA transfection experiment, DKK3 expression was inhibited by about 
50% in the DKK3-siRNA+AngII group and DKK3-siRNA group compared to the 
NC-siRNA group (Fig. S1a). We found that cardiac hypertrophy was successfully 
alleviated in the DKK3 overexpression group compared to that in the control group.  
Representative images of each group are shown in Fig. 1d.  The inhibition of cardiac 
hypertrophy was also evidenced by the decreased ratios of HW/BW and HW/TL. The 
value of BW was close to that of TL, and there were no significant differences between 
them; thus, we showed only HW/TL in Fig. 1e. The cross-sectional area of 
cardiomyocytes examined with wheat germ agglutinin (WGA) staining revealed an 
alleviation of AngII- induced cardiac hypertrophy in the DKK3-overexpressing group 
(Fig. 2a and 2b). RT-PCR showed that the hypertrophic markers atrial natriuretic 
peptide (ANP) and beta-myosin heavy chain (β-MHC) were markedly decreased in 
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AngII-treated DKK3-overexpressing mice compared to those in AngII-treated 
adenovirus-null mice (Fig. 2c). 
Tissue Doppler imaging was adopted to evaluate the function of mouse hearts 
treated with different drugs. The echocardiography results indicated that DKK3 
elevated the decreased LVEF, E/A ratio and FS in AngII-perfused mice. In contrast, 
the left ventricular (LV) posterior wall thickness at diastole (LVPWd) decreased in the 
group that was injected with the DKK3 adenovirus and perfused with AngII (Fig. 
2d-2h) 
Blood pressure rose in the AngII-perfused groups (OV+AngII: 
167.8±21.3/115.9±12.3 mmHg vs. AD+AngII: 159.3±19.8/112.3±10.4 mmHg) 
compared to that in the saline-pumped groups (OV:122.5±15.6/91.3±6.7 mmHg vs. 
AD:119.7±13.5/88.7±5.7 mmHg), but no significant differences were detected 
between the OV+AngII and AD+AngII groups or the OV and AD groups.  
3.2 Overexpression of DKK3 inhibits AngII-induced cardiac fibrosis  
To further determine whether DKK3 overexpression inhibits AngII- induced 
cardiac fibrosis, a histological examination was performed on heart sections. 
Masson’s trichrome staining revealed a significant decrease in interstitial and 
perivascular fibrosis in DKK3-injected and AngII- infused mice compared with those 
in vehicle- injected mice (Fig. 3a-3b). Immunohistochemistry staining confirmed that 
the levels of the fibrotic markers collagen I and collagen III were significantly 
down-regulated in DKK3-treated mice compared with those in vehicle-treated 
animals after the AngII infusion (Fig. 3a and 3c). The levels of collagen I and 
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collagen III were detected by WB, which were similar to those detected by 
immunohistochemical staining (Fig. 3d-3e). In the siRNA transfection experiment, 
inhibition of DKK3 by AngII increased the expression levels of collagen I and 
collagen III compared to NC-siRNA transfection. Collagen I expression in the 
DKK3-siRNA+AngII group was even higher than that in the NC-siRNA+AngII group, 
showing the inhibitory role of DKK3 in collagen synthesis in the heart (Fig. S1b-S1c). 
3.3 DKK3 overexpression inhibits the inflammatory reaction caused by AngII 
perfusion 
Cardiac hypertrophy is a type of inflammatory disease. WB showed that 
expression of the inflammatory cytokine IL-6 was decreased in the DKK3 
overexpression group in vitro (Fig. 4a-1 and 4a-2). Based on the results of the in vivo 
histological analysis, the levels of IL-6, T cells and macrophage markers CD45 and 
CD68 were reduced in the DKK3 group compared with those in the vehicle group 
(Fig. 4b1-4b4). Moreover, ELISAs revealed a dramatic decrease in the expression of 
proinflammatory cytokines, including IL-1β and TNF-α, in DKK3-treated mice 
compared with that in controls after the AngII infusion (Fig. 4c-4d). 
3.4 DKK3 overexpression reduces the expression of matrix metalloproteinases 
(MMPs) in CFs 
Fibroblasts secrete MMPs, which are involved in matrix degradation. The 
accumulated amount and increasing activity of MMPs represents the severity of organ 
fibrosis. WB was used to evaluate the content of MMPs in vitro. MMP2 and MMP9 
expression was increased in the AD+AngII and AD groups, but decreased in the 
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OV+AngII group (Fig. 4e-1 and 4e-2). 
3.5 DKK3 overexpression inhibits proliferation and promotes apoptosis in CFs 
As most collagens are produced by CFs, CF proliferation seems to be a crucial 
event in cardiac hypertrophy pathophysiology. According to the results of the EdU 
assays, DKK3 overexpression inhibited CF proliferation in the OV+AngII group (Fig. 
5a-1 and 5a-2). Meanwhile, the apoptosis markers bax and bcl-2 were detected by 
WB and a higher ratio was detected in the OV+AngII group, indicating that apoptosis 
increased upon DKK3 overexpression (Fig. 5b). 
3.6 DKK3 overexpression reduces the level of phosphorylated ADAM17, thus 
increasing the ACE2 content and Ang-(1-7) concentration 
 Immunoblots were performed using total proteins from CFs to examine the 
relationships between DKK3, ADAM17 and ACE2. DKK3 inhibited ADAM17 
phosphorylation, but the total ADAM17 level exhibited little change (Fig. 5c). 
Meanwhile, the AngII- induced decrease in ACE2 expression was restored by DKK3 
(Fig. 5e). Based on the results obtained from the in vitro assessment, ADAM17 
phosphorylation decreased and ACE2 expression increased in the OV+AngII group 
compared to those in the AD+AngII group (Fig. 5d and 5f). We also performed 
immunohistochemistry to detect ACE2 expression and observed increased ACE2 
expression in the OV+AngII group compared to that in the AD+AngII group (Fig. 
5g-1 and 5g-2). Then, we detected the plasma concentration of Ang-(1-7) in mice and 
found that plasma Ang-(1-7) concentrations in the OV+AngII group were elevated 
about two-fold compared to those in the AD+AngII group. There was no significant 
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difference in plasma Ang-(1-7) concentration among the other three groups (Fig. s2c). 
This result demonstrated that overexpression of DKK3 elevated ACE2 expression, 
which then elevated Ang-(1-7) expression. In the siRNA transfection experiment, 
DKK3-siRNA transfection increased the level of phosphorylated ADAM17 compared 
to NC-siRNA transfection with or without AngII; on the other hand, the level of ACE2 
decreased (Fig. S1d-1e).   
3.7 The anti-hypertrophic and anti-fibrotic effects of DKK3 overexpression are 
linked to its inhibition of the GSK-3β/β-catenin pathway 
We examined the levels of the GSK-3β/β-catenin pathway in vitro to further 
investigate the mechanism by which DKK3 regulates AngII- induced ECM deposition. 
DKK3 overexpression reduced the p-GSK-3β and active β-catenin levels (Fig. 6b and 
6d). Immunofluorescence staining revealed only a very weak β-catenin signal in the 
nuclei of CFs in the OV+AngII group, but the signal was markedly strengthened in 
the nuclei of CFs treated with AngII alone (Fig. 6a). Based on the immunoblot 
analysis, p-GSK-3β was also reduced by DKK3 in vivo (Fig. 6c). In the siRNA 
transfection experiment, DKK3 silencing increased the levels of activated β-catenin 
and phosphorylated GSK-3β in the presence of AngII compared to NC-siRNA 
transfection (Fig. S1f-S1g). Thus, DKK3 influenced ADAM17/ACE2 activity to 
reduce the detrimental effects of AngII, potentially by suppressing GSK-3β 
phosphorylation and β-catenin accumulation in the nucleus. 
3.8 DKK3 overexpression protected against cardiac hypertrophy by regulating the 
TGF-β1/Smad3 pathway 
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As is known, the TGF-β1 and Smad pathway promotes collagen generation in many 
tissues and diseases [21-23]. Therefore, in addition to the ADAM17/ACE2 and 
GSK-3β/β-catenin pathways, we investigated the TGF-β1/Smad3 pathway. As 
expected, the levels of TGF-β1 and phosphorylated Smad3 increased in groups treated 
with AngII but decreased when DKK3 was overexpressed by adenoviruses in vitro; on 
the contrary, CFs treated with DKK3-siRNA plus AngII exhibited increased 
expression levels of TGF-β1 and Smad3 (Fig. S1h-S1i, S2a-2b).  
Discussion 
In this study, low levels of DKK3 expression were observed in the hypertrophic 
myocardium, and DKK3 overexpression reversed the effects of AngII on cardiac 
hypertrophy and fibrosis. During cardiac remodeling, the most apparent change is 
enlargement of the heart, which is due to hypertrophy and fibrosis. Based on our 
observations of the mouse model of AngII- induced cardiac remodeling, DKK3 
overexpression ameliorated cardiac hypertrophy by attenuating cardiomyocyte 
enlargement and the increase in HW/BW and HW/TL and by decreasing the 
expression of fetal genes, including ANF and β-MHC (Fig.1e, 2a, 2b and 2c), along 
with fibrosis, during remodeling by decreasing the collagen synthesis (Fig. 3a and 
3d). 
Cardiac hypertrophy and fibrosis are induced by many factors, such as 
mechanical pressure overload or the humoral factors endothelin and AngII. AngII, the 
most important constituent of the renin-angiotensin-aldosterone system (RAAS), 
exerts direct effects on myocardial cells and CFs, causing cell growth, hypertrophy, 
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and extracellular matrix accumulation [24, 25]. Numerous interactive signaling 
pathways transduce the AngII-induced pro-fibrosis and pro-hypertrophy signals to the 
nucleus, leading to the reprogramming of gene expression. Methods that transform the 
excessively detrimental AngII into a protective factor must benefit the injured heart. 
The ACE2/Ang 1-7/Mas receptor axis is a physiological antagonist of the RAS, where 
ACE2 cleaves AngII and generates Ang-(1-7) [9]. Ang-(1-7) is a factor that protects 
the cardiovascular system and has a role in improving vascular endothelial function 
by decreasing MMP-9 expression and reducing neutrophil and macrophage 
infiltration [10, 11]. Guo et al found that Ang-(1-7) attenuates AngII-induced cardiac 
hypertrophy by stimulating the Sirt3-mediated deacetylation of FoxO3a and SOD2 
expression. In our study, we also detected the serum concentration of Ang-(1-7) and 
found that it was elevated by approximately two fold compared to the vehicle group 
when DKK3 was overexpressed. Interestingly, overexpression of DKK3 without AngII 
perfusion did not change the concentration of Ang-(1-7), suggesting that DKK3 
overexpression was pathology dependent and harmless (Fig. S2c). Therefore, we 
proposed the hypothesis that DKK3 overexpression may increase ACE2 expression 
and thus affect the cardiac impairment caused by AngII. Immunoblots of cell and 
tissue lysates were performed to verify this hypothesis. The perfusion of AngII in 
mice and the addition of AngII to the CFs decreased ACE2 expression, which was 
restored by DKK3 overexpression (Fig. 5e and 5f). In contrast, DKK3 silencing 
resulted in decreased of ACE2 expression (Fig. S1e). According to the 
immunohistochemical staining, DKK3 overexpression also increases ACE2 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
expression in the heart tissue (Fig. 5g-1, 5g-2). We examined the pathway upstream of 
ACE2 to identify the intracellular mechanism by which DKK3 influenced ACE2. 
AngII was recently shown to induce ACE2 shedding by promoting ADAM17 activity 
through a positive feedback mechanism [27]. Therefore, we examined the relationship 
between DKK3 and ADAM17. In our study, the overexpression of DKK3 in CFs had 
no effect on the total ADAM17 level, but influenced its phosphorylation state. 
P-ADAM17 levels decreased in the OV+AngII and OV groups (Fig. 5c and 5d) and 
increased in the DKK3-siRNA group (Fig. S1d). 
In addition to the ADAM17/ACE2 pathway, DKK3 also inhibits the 
GSK-3β/β-catenin signaling pathway. GSK-3β, an anti-hypertrophic kinase, is 
inactivated when it is phosphorylated following AKT activation [28]. Consequently, 
GSK-3β is recruited to the Frizzled receptor, thereby inhibiting GSK-3β and reducing 
its availability for binding to β-catenin. β-catenin is an adhesion-associated protein 
whose phosphorylation causes its degradation in the cytoplasm. As a consequence,  
accumulated β-catenin in the cytoplasm is shuttled into the nucleus, which augments 
the expression of pro-hypertrophic and pro-fibrosis genes [29, 30]. The signaling 
function of β-catenin is primarily regulated by alterations in its stability. Wnt 
signaling induces stabilization of cytoplasmic β-catenin [31]. Here, DKK3 
overexpression resulted in the inactivating phosphorylation of GSK-3β (Fig. 6b-6c). 
DKK3 is a secreted protein in the dickkopf family and acts as an inhibitor of 
Wnt/β-catenin signal depending on the cellular context [32]. Hirschy A et al. reported 
that mice expressing a non-degradable form of β-catenin developed dilated 
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cardiomyopathy and died after 5 months of age [33]. In our study, the accumulation of 
β-catenin in the nucleus was suppressed in the DKK3 overexpression group, thus 
alleviating AngII- induced hypertrophy (Fig. 6a and 6d). Meanwhile, opposite results 
were obtained in the siRNA experiment (Fig. S1f-1g). In this study, the excess 
accumulation of ECM components, including collagen I and collagen III, decreased in 
the DKK3 overexpression group and increased in the DKK3-siRNA group, indicating 
that DKK3 suppressed AngII- induced cardiac fibrosis (Fig. 3a-3e, S1b-S1c). 
Moreover, DKK3 overexpression improved cardiac function, as indicated by the 
LVEF, LVPWD, E/A and FS values, and blocked the changes in cardiac structure in 
AngII-infused mice (Fig. 2d-2h).  
Due to the close relationship between the TGF-β1/Smad3 pathway and collagen 
synthesis, we examined these two molecules both in the DKK3 overexpression 
experiment and siRNA silencing experiment. Consistent with previous reports [21-23], 
increased collagen expression accompanied the increase in TGF-β1 and Smad3 
expression. Moreover, DKK3 overexpression reduced this abnormity in TGF-β1 and 
Smad3 expression caused by AngII, whereas DKK3-siRNA aggravated it (Fig. S1h-S1i, 
S2a-2b).  
The mechanism by which DKK3 decreases the synthesis of ECM became the 
next focus of this study. Fibroblasts are known to secrete ECM, such as collagen I and 
III, which contribute to the development of cardiac remodeling and fibrosis. Similarly, 
MMPs, which are involved in matrix degradation, are also secreted by fibroblasts. 
The accumulated amount and increasing activity of MMPs indicates the severity of 
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organ fibrosis [34]. In the present study, MMP2 and MMP9 activity increased in 
AngII-treated fibroblasts, which was reversed by DKK3 overexpression (Fig. 4e-1 
and 4e-2). This finding suggests that the protective role of DKK3 might be partially to 
regulate the MMP balance. 
Inflammatory signaling in cardiomyocytes has recently been found to occur as 
part of the pathophysiologic process in response to cardiac hypertrophy, fibrosis, and 
dysfunction in heart disease. IL-1β, TNF-α and IL-6 have been shown to exert a 
causative effect on the development of cardiac hypertrophy and dysfunction [35-37]. 
In our study, fibroblasts treated with AngII exhibited increased expression of IL-1β, 
TNF-α and IL-6, which was suppressed by DKK3 overexpression (from Fig. 4a-1 to 
4d). This result was consistent with a report that IL-6 genetic deletion ameliorated 
angiotensin-II- induced cardiac hypertrophy and fibrosis [38]. In addition to IL-6, 
macrophages and T cells also participate in the development of cardiomyopathy [39]. 
An experiment in which macrophages were non-selectively depleted at an early stage 
reduced the cardiac inflammatory response and improved cardiac function [40]. 
Immunohistochemistry in our experiment showed a decline in CD45 and CD68 
contents when cells were treated with DKK3 compared to those in cells treated with 
AngII (Fig. 4b-1, 4b-3 and 4b-4). 
The apoptosis of cardiomyocytes, which react to different pathogeneses, is an 
important part of cardiac hypertrophy. Inflammation and oxidative stress are directly 
related to apoptosis in hypertrophic hearts of diabetic patients and animals [41-43]. 
We performed EdU staining to evaluate the proliferation of CFs and WB of bcl-2 
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family proteins to detect apoptosis of CFs. Bcl-2 proteins are members of the Bcl 
family that can prevent cell death and increase cell proliferation and growth. In 
contrast, bax is a protein that can promote cell death [44]. In this study, the ratio of 
bax/bcl-2 increased in the DKK3 overexpression group compared to that in the 
AngII-treated group (Fig. 5b). Meanwhile, the percentage of EdU-positive cells in the 
DKK3 overexpression group decreased compared to that in the AngII-treated group 
(Fig. 5a-1 and 5a-2).  
Our study has a few limitations. For example, the precise relationship between 
the ADAM17/ACE2 pathway and the GSK-3β/β-catenin signaling pathway requires 
further study. Overexpression of components of the GSK-3β/β-catenin pathway 
should verify whether DKK3 loses its inhibitory effect on ADAM17. Therefore, our 
future studies will perform this overexpression experiment both in vitro and in vivo.  
Additionally, the use of transgenic animals and the knockdown of the DKK3 gene 
would provide better data to explain the effect of DKK3. Although we performed 
DKK3-siRNA experiments in the present study to evaluate the effects of DKK3 
knockdown, transgenic animal experiments would provide better data. Moreover, 
using neonatal CFs to mimic adult disease is less accurate, as the phenotype and 
response of adult CFs to AngII and DKK3 overexpression could be very different. 
Embryonic stem cell-derived adult CFs may help address this problem and will be 
considered in our subsequent work. 
In conclusion, the current study indicates that DKK3 overexpression effectively 
reduces cardiac hypertrophy and fibrosis and improves cardiac function in an 
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AngII-perfused mouse model. These cardioprotective properties appear to be due to 
direct influences on the ADAM17/ACE2 pathway that may be achieved via the 
inhibition of the GSK-3β/β-catenin signaling pathway. Importantly, DKK3 attenuates 
AngII- induced MMP2 and MMP9 expression and inhibits collagen synthesis in vitro. 
Furthermore, DKK3 overexpression alleviated the inflammatory reaction and 
proliferation of CFs caused by AngII. Above all, these results confirmed for the first 
time that DKK3 exerts cardiac protective effects against cardiac remodeling. 
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Legend 
Fig. 1: An elevated DKK3 level alleviates AngII- induced cardiac hypertrophy. (a-b) 
Immunoblots showing the DKK3 protein level in mouse hearts and CFs. Mouse hearts 
were removed from treated animals, as described in the Methods section, and proteins 
were extracted to perform the WB experiment. At least three animals from each group 
were chosen. Proteins were extracted from CFs after treated with adenovirus or 
vehicle for 24 h and Ang II for additional 48 h. In subsequent experiments, WBs of 
CFs were performed as described here, unless stated otherwise. The experiment was 
repeated three times. (c) The DKK3 level in mouse serum was analyzed using an 
ELISA kit after the animals were sacrificed at the end of the experiment. (d) 
Representative image of the heart size. (e) Mouse body weights and tibial lengths 
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were recorded before the animals were euthanized, and the heart weight was recorded 
at the moment hearts were excised and washed. The HW/TL ratios was calculated and 
presented as an average value. *P<0.01, #P<0.05. HW represents heart weight. TL 
represents tibia length. HT represents heart tissue. CF represents cardiomyocyte 
fibroblast. OV represents overexpression adenovirus. AD represents adenovirus 
vehicle. AngII represents angiotensin II. NC represents negative control. 
Fig. 2: DKK3 overexpression alleviates AngII- induced cardiac dysfunction and 
hypertrophy. Cardiac hypertrophy was reflected by measurements of molecular 
markers and cardiomyocyte staining, and cardiac function was evaluated using 
echocardiograms. (a) RT-PCR analysis of ANP and β-MHC levels (two markers of 
cardiac hypertrophy) in the total RNA extracted from mouse hearts. (b and c) WGA 
staining of heart sections showing the cross-sectional area of cardiomyocytes. (d) 
M-mode echocardiograms and pulsed-wave Doppler echocardiograms of the mitral 
inflow. (e) Early to late mitral flow (E/A). (f) Fractional shortening (FS). (g) Left 
ventricular ejection fraction (LVEF). (h) Thickness of the left ventricular diastolic 
posterior wall (LVPWD). Each experiment was repeated three times. ^P<0.05 
compared with the AD+AngII group. &P<0.05 compared with the OV group. OV 
represents overexpression adenovirus. AD represents adenovirus vehicle. AngII 
represents angiotensin II. WGA represents wheat germ agglutinin staining.  
Fig. 3: DKK3 overexpression inhibits AngII- induced cardiac fibrosis. The ECM 
content was detected by Masson’s trichrome staining, immunostaining and 
immunoblots. (a) Masson’s trichrome staining and immunostaining for collagen I and 
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collagen III in heart sections. Scale bar: 20 μm. (b) Quantitative analysis of 
myocardial fibrosis. (c) Quantitative analysis of collagen I and collagen III expression. 
(d) Immunoblot analysis of the collagen I and collagen III proteins in CFs. (e) 
Quantitative analysis of the levels of the collagen I and collagen III proteins. The 
experiment was repeated three times. ^P<0.05 compared with the AD+AngII group. 
&P<0.05 compared with the OV group. ΔP<0.05 compared with the AngII group. 
лP<0.05 compared with the NC group. OV represents overexpression adenovirus. AD 
represents adenovirus vehicle. AngII represents angiotensin II. CF represents 
cardiomyocyte fibroblast. 
Fig. 4: DKK3 overexpression inhibits the inflammatory reaction and increasing 
MMPs activity caused by AngII perfusion. The inflammatory reaction was assessed 
by analyzing the levels of the IL-6 protein in CFs, inflammatory cell infiltration, and 
cytokine levels in serum. (a) Immunoblot analysis of the IL-6 protein in CFs. (b) 
Immunostaining for IL-6, CD45 and CD68 in heart sections. The levels of CD45 and 
CD 68 represented the number of T cells and macrophages that had infiltrated the 
heart, respectively. (c-e) Quantitative analysis of IL-6, CD45 and CD68 levels. (f-g) 
ELISA of IL-1β and TNF-α level in mouse serum. (h) Immunoblot analysis of the 
MMP2 and MMP9 proteins in CFs. Each experiment was repeated three times. 
^P<0.05 compared with the AD+AngII group. &P<0.05 compared with the OV group. 
ΔP<0.05 compared with the AngII group. лP<0.05 compared with the NC group. OV 
represents overexpression adenovirus. AD represents adenovirus vehicle. AngII 
represents angiotensin II. CF represents cardiomyocyte fibroblast. 
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Fig. 5: DKK3 overexpression inhibits proliferation and promotes apoptosis in CFs, 
and its anti-AngII effect was linked to the inhibition of the ADAM17/ACE2 pathway. 
(a) Laser confocal microscopy of EdU staining showing a decrease in CF proliferation 
in the OV+AngII group. Nuclei are stained blue with DAPI; red indicates the cells 
undergoing proliferation. (b) The EdU-positive index is expressed as a percentage of 
cell counts. (c) Immunoblot analysis of bax and bcl-2 proteins in CFs. The results are 
displayed as the bax/bcl-2 ratio and show an increase in apoptosis in the OV+Ang II 
group. (d-g) Immunoblot analysis of the ADAM17 and ACE2 proteins in CFs and 
heart tissues. ADAM17 protein was inhibited in the OV+AngII group while ACE2 
protein increased compared to the AD+AngII group. (h- i) Immunostaining for ACE2 
in heart sections and the corresponding quantitative analysis. ^P<0.05 compared with 
the AD+AngII group. &P<0.05 compared with the OV group. ΔP<0.05 compared with 
the AngII group. лP<0.05 compared with the NC group. ΚP<0.05 compared with the 
AD group. ηP<0.05 compared with the NC group. DKK3-OV represents DKK3 
overexpression adenovirus. AD-null represents adenovirus vehicle. AngII represents 
angiotensin II. CF represents cardiomyocyte fibroblast. HT represents heart tissue. 
EDU represents 5-Ethynyl-2’-deoxyuridine staining, a kind of cell proliferation assay. 
Fig. 6: The regulation of ADAM17/ACE2 pathway of DKK3 is linked to its inhibition 
of the GSK-3β/β-catenin pathway. (a) Immunofluorescence staining showing the 
decreased accumulation of active β-catenin in the nucleus of the OV+AngII group, 
indicating that the β-catenin pathway was inhibited. (b-d) Immunoblot analysis of the 
GSK-3β and β-catenin proteins in CFs and heart tissues. The p-β-catenin protein was 
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detected in nuclear protein extracts, and all other proteins were detected in total 
protein extracts. GSK-3β and β-catenin proteins were inhibited in the OV+AngII 
group compared to the AD+AngII group. ^P<0.05 compared with the AD+AngII 
group. ΔP<0.05 compared with the AngII group. лP<0.05 compared with the NC 
group. DKK3-OV represents DKK3 overexpression adenovirus. AD-null represents 
adenovirus vehicle. AngII represents angiotensin II. CF represents cardiomyocyte 
fibroblast. HT represents heart tissue. 
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Highlights 
 The current study indicates that DKK3 overexpression effectively reduces 
cardiac hypertrophy and fibrosis and improves cardiac function in an 
AngII-perfused mouse model. 
 We made some innovations in the mechanism. 
 Firstly, we reported the relationship between DKK3 and the 
ADAM17/ACE2 pathway for the first time. Secondly, we revealed the 
role of GSK-3β/β-catenin signaling pathway in DKK3 overexpression 
model. 
 Thirdly, we determined the MMPs expression together with inflammatory 
reaction and proliferation of CFs in hypertrophy heart. 
 Above all, these results confirmed for the first time that DKK3 exerts 
cardiac protective effects against cardiac remodeling by regulating 
ADAM17/ACE2 pathway activity and inhibiting the GSK-3β/β-catenin 
pathway. 
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